Monday, June 13, 2016

BRIEF-Mesoblast provides update on global heart failure program

* Mesoblast says regains worldwide rights to cardiovascular field for its cell therapy

platform; no financial consideration to teva pharmaceuticals

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)